Arcus Q2 net loss $91M, revenue $41M; casdatifan pipeline advances with new collaborations

Arcus Biosciences, Inc.

Net loss of $91M in Q2 2026 vs. $0 in Q2 2025; revenue fell to $41M from $160M.
Cash $775M at June 30; expects ~$600M year-end; runway to at least H2 2028.
Casdatifan: multiple data readouts H2 2026; new collaborations with BMS, Summit, AVEO.
Gilead relinquishes three board seats; PACIFIC-8 Phase 3 study discontinued.
Quemliclustat gets EU orphan drug designation; PRISM-1 Phase 3 results due H1 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.